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A B S T R A C T
Over the past ten years, the global biopharmaceutical market has remarkably grown, with ten over the top
twenty worldwide high performance medical treatment sales being biologics. Thus, biotech R&D (research and
development) sector is becoming a key leading branch, with expanding revenues. Biotechnology oﬀers con-
siderable advantages compared to traditional therapeutic approaches, such as reducing side eﬀects, speciﬁc
treatments, higher patient compliance and therefore more eﬀective treatments leading to lower healthcare costs.
Within this sector, smart nanotechnology and colloidal self-assembling systems represent pivotal tools able to
modulate the delivery of therapeutics. A comprehensive understanding of the processes involved in the self-
assembly of the colloidal structures discussed therein is essential for the development of relevant biomedical
applications.
In this review we report the most promising and best performing platforms for speciﬁc classes of bioactive
molecules and related target, spanning from siRNAs, gene/plasmids, proteins/growth factors, small synthetic
therapeutics and bioimaging probes.
1. Introduction
The application of emerging nanotechnology to biomedical and
pharmaceutical research allowed real progresses in the development of
temporal and site speciﬁc drug delivery, leading to a new ﬁeld of re-
search deﬁned as nanomedicine which nowadays is one of key ﬁelds of
research [1]. Such a breakthrough was supported by the advanced
scientiﬁc knowledge and technological development of diﬀerent types
of systems, such as carbon nanomaterials (fullerenes, nanotubes) [2],
polymeric carriers (micelles, niosomes, nanoparticles, nanogels and
macrogels) and lipid-based nanosystems (lipid nanovesicles, cubosomes
and solid lipid nanoparticles) [3].
The use of colloidal delivery systems proved to be an eﬃcient ap-
proach to improve the bioavailability and pharmacokinetics of small
therapeutic molecules; hereby we describe the most recent advances in
the ﬁeld, with particular focus on the most suitable system depending
on the desired bioactive molecule to be delivered.
2. Hydrogels and colloidal structures for drug delivery
Hydrogels can be deﬁned as coherent systems composed by a three-
dimensional ﬁbrous network, usually of polymeric origins, containing a
large amount of aqueous phase, which cannot dissolve the network due
to the presence of interconnections, called crosslinks [4]. Interestingly,
these systems are able to host a remarkable amount of the aqueous
phase (the solid network volume fraction can be lower than 1%),
whereas showing rheological-mechanical properties closer to solids
rather than to liquids [4], thus mimick living tissues [5]. Hydrogels can
be classiﬁed according to the nature of the crosslinks, their origin,
composition, charge and conﬁguration [6]. From a crosslinking point of
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view, hydrogels can be chemical or physical. In chemical hydrogels,
crosslinks between diﬀerent chains (ﬁbers) are strong, permanent and
punctual, due to covalent bonds. Conversely, physical hydrogels are
characterized by either chains topological entanglements (spaghetti-like
conﬁguration, Fig. 1) or physical interactions (this being typical of
polysaccharides such as glucans and xanthan) such as H-bonds, ionic,
Coulombic, van der Waals, dipole-dipole and hydrophobic interactions.
Additional junctions can occur, with long chain segments departing
from the ordered junction zones towards further chains, generating a
polymeric three-dimensional network. Physical interactions are often
transient, with non-strong bonding points, able to lead to a network
characterized by a constant average crosslink density (i. e. moles of
crosslinks per gel unit volume) and a time dependent spatial distribu-
tion of crosslinks. Thus, network meshes conﬁgure as a dynamic equi-
librium, due to chains segments size and related Brownian motions,
being the average mesh number and dimension constant [4,7]. Ordered
zones formation is favored/hindered by environmental conditions such
as temperature and ionic strength [8]. For instance, agarose undergoes
a thermo-reversible gelation process occurring when hot solutions are
cooled below ~40 °C. In the hot state, agarose chains appear to behave
as stiﬀened coils whereas, after cooling, a particularly extensive re-or-
ganization takes place, resulting in a hydrogel aggregation, at very low
polymer concentrations (≥0.1% w/w) [9]. Physical crosslinks are
usually associated with mechanically weak gels, except for e.g., the case
of alginates, where a strong physical hydrogel arises. Alginates are
linear polymers of vegetal or bacterial origin containing β-D-man-
nuronic (M) and α-L-guluronic (G) acid [10], where the addition of
diﬀerent cations, such as Ca2+, Cu2+, Ba2+ and Sr2+, can induce
gelation. These cations bind to stretches of guluronic acid residues
within the polysaccharide chain, leading to the formation of junctions,
which physically hold together the polysaccharide chains in a 3D
continuum according to the egg-box model (see Fig. 1). Pectins are
another outstanding example of polysaccharides leading to strong
physical hydrogels, triggered by divalent cations, although with some
changes connected to the existence of neutral sugars in the chains (that
should hinder inter-chain association) and the methylation of some
galactunorate residues (that do not contribute to the electrostatic ion
binding). Pectin is contained in the primary cell walls of terrestrial
plants, thus it is an important polysaccharide that allows primary cell
wall extension and plant growth. Pectin polymers are widely employed
for industrial purposes as gelling agents in food, stabilizers in fruit
juices and milk drinks and as ﬁlling in medicines [10,11].
With reference to their origin, hydrogels can be natural or synthetic.
Among the plethora of natural hydrogels, those based on agar, collagen,
chitosan, alginate, hyaluronic acid, gelatin, ﬁbrin and polysaccharides
(animal, vegetal and microorganisms origin [12]) are most represented
[13]. Conversely, D,L-lactide-co-glycolide (PLGA), polyamidoamine
(PAMAM), poly(caprolactone-co-ethylethylene phosphate) (PCLEEP)
and poly(N-vinyl-2-pyrrolidone) PVP can be included in the synthetic
class.
For homopolymeric hydrogels, the network is formed towards a
polymer constituted by a single species of monomer, whereas in copo-
lymeric hydrogels two or more diﬀerent monomer species compose the
chains of the polymeric network. Finally, interpenetrating polymeric
hydrogels (IPN) are made up of two (or more) independent cross-linked
synthetic and/or natural polymeric chains [14].
Hydrogels can be categorized depending on their charge features, as
nonionic (neutral), ionic (anionic or cationic), amphoteric electrolyte
(ampholytic) containing both acidic and basic groups, zwitterionic
(polybetaines) containing both anionic and cationic groups in each
structural repeating unit. From a conﬁguration point of view, they can
be classiﬁed as amorphous, semicrystalline (a mixture of amorphous and
crystalline phases) and crystalline [6].
Any technique that allows the formation of bonds between poly-
meric chains can lead to the formation of hydrogels. At this purpose,
chemical reaction, ionizing radiations, physical interactions (e.g. en-
tanglements and electrostatics) and crystallite formation can be used.
Moreover, hydrogels can be obtained thanks to polymerization tech-
niques, including bulk, solution, and suspension polymerization [6].
However, an aqueous environment and room temperature are manda-
tory to perform a safe crosslinking procedure, in order to obtain hy-
drogels from a solution containing the polymer and hydrophilic drugs
that can easily undergo denaturation such proteins, peptides and drugs
based on nucleic acid (NABDs). For example, these requirements are
perfectly accomplished by the ionic gelation of polysaccharides such as
alginates and galacturonic [15]. Ionic gelation can also occur in the
case of polycations with an anion as the crosslinker. Speciﬁcally, the
ionic interaction between chitosan (polycation) and the trivalent ne-
gatively charged glycerol phosphate was shown to induce hydrogel
formation [16].
Both macroscopic and micro/nanoscopic properties of hydrogels
play an important role in biomedical applications. It has been recently
demonstrated that, in three-dimensional culturing, the (macroscopic)
viscoelastic properties of hydrogels used as substitutes of natural ex-
tracellular matrix (EM) can aﬀect cells behavior in terms of spreading,
proliferation and diﬀerentiation. Chaudhuri and co-workers [17] de-
monstrated that the osteogenic diﬀerentiation of mesenchymal stem
cells (MSCs) strictly depends on the viscoelastic properties of the algi-
nates hydrogels used as substitute of EM. In detail, mesenchymal stem
cells form mineralized, collagen-1-rich matrix similar to bone only
when they are in contact with highly elastic hydrogels.
On the other hand, when hydrogels are created to release active
agents, the mesh size distribution of the three-dimensional network
(nanoscopic property) represents a relevant characteristic. Indeed,
mesh size distribution is a key parameter ruling the release kinetics of
an embedded drug and it can be essential to protect hydrogel cargo
(drug, cells and so on) by external factors such as enzymes and the
immune system agents. An outstanding example is represented by
Fig. 1. Representative examples of chemical and physical crosslinks occurring in hy-
drogels. Based on the crosslinks nature, hydrogels can be deﬁned as physical or chemical.
In the ﬁrst case, crosslinks are weak and are due to either polymer chains topological
entanglements (A) or weak physical interactions (B) such as H-bonds, ionic, Coulombic,
van der Waals, dipole-dipole and hydrophobic interactions. Conversely, in the case of
chemical crosslinks, crosslinks between chains are strong and permanent (C–D, covalent
bonds).
Adapted from [4].
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hydrogel based implantable systems, as well as immunoisolant mem-
branes, which serve to protect encapsulated pancreatic cells (aimed at
the production of insulin) from antibodies [18].
In terms of release mechanisms, hydrogels drug depot can be con-
trolled by physical, physicochemical and system related strands [19].
Swelling/shrinking processes are related to physical phenomena,
whereas erosion, drug dissolution (recrystallization), drug transport (by
diﬀusion and convection) and drug interaction throughout the matrix
structure constitute the physicochemical phenomena. System related
mechanisms depend on the initial drug distribution and concentration
inside the hydrogel, hydrogel geometry (cylindrical, spherical, etc.) and
size distribution in the case of polydispersed ensembles of hydrogels.
The swelling/shrinking process occurs upon variation of external
factors (temperature and pH, more frequently), inducing a new equi-
librium condition or when the dry hydrogel is in contact with an aqu-
eous environment. The abovementioned process relies on the chemical
potential diﬀerence between the water inside and outside the hydrogel
[20].
Hydrogel erosion can be ruled out by chemical and/or physical
factors. Erosion can be deﬁned as peripheral or heterogeneous, when it
aﬀects only hydrogel surface. On the other hand, bulk or homogeneous
erosion involves the whole hydrogel volume [21]. Chemical erosion is
due to hydrolytic/enzymatic degradation of polymeric chains, while
physical erosion depends on chains disentanglement due to the hy-
drodynamic conditions of the external aqueous environment.
Stability restrictions often require hydrogels storage in the dry
status. In such a case, drug release will begin as soon as an external
aqueous ﬂuid diﬀuses towards the polymeric network and a key step
can be represented by the drug dissolution over the water permeating
the network. When metastable bioactive molecules like polymorphs,
amorphous or nano-crystalline drugs are present in the dry hydrogel,
the dissolution process may correlate with recrystallization which leads
to the formation of a new, more stable, drug crystallographic organi-
zation induced by the contact with the absorbed water [22].
Bioactive molecule depot and mobility towards colloidal networks
can be strongly aﬀected by the hydrogel mesh size distribution, as well
as by the drug physical and chemical interactions with the 3D poly-
meric network [23]. For instance, drug adsorption/desorption phe-
nomena may be due to electrostatic interactions, such as charged
polypeptides and antibiotics in collagen matrices [24]. Moreover,
bioactive molecule delivery can be inﬂuenced and driven by hydrogen
bonds [25], lipophilic [26], as well as non-covalent interactions among
imprinted polymeric networks and template molecules that need to be
recognized in a physiological environment [27].
Colloidal and hydrogel frameworks are key structures for several
bioactive molecule controlled delivery, with a speciﬁc application for
Nucleic Acid based Drugs (NABDs) release.
NABDs are constituted by short sequences of either DNA or RNA,
including antisense oligonucleotides, decoys oligonucleotides, apta-
mers, triple helix forming oligonucleotides, DNAzymes, Ribozymes,
small interfering RNAs (siRNAs) and micro interfering RNAs (miRNAs)
[12]. Despite their massive therapeutic potential towards diﬀerent
hyper-proliferative diseases [28], their daily clinic application is still
very limited because of their rapid degradation by several enzymes,
such as blood and cellular nucleases [29]. Moreover, as detailed in the
next section (Section 3.2), considering that both NABDs and cellular
membranes are negatively charged, crossing the cellular membrane
represents the core drawback, due to electrostatic repulsion. Thus, de-
livery of naked NABDs cannot lead to exploit their therapeutic activity.
Delivery vectors can be divided into three classes, based on their size
[30]: nano, micro and macro scales vectors. Nanoscale vectors are re-
presented by polycationic polymers or lipids that self-assemble with
NABDs to form polyelectrolyte complexes (poly- or lipo-plexes, re-
spectively, as detailed in Section 3). Microscale vectors can be outlined,
for example, as hydrogels entrapping the poly- or lipo-plexes. Macro-
scale vectors are three dimensional matrices (such as hydrogels) that
can host microvectors containing, in turn, poly- lipo-plexes to give rise
to a chimeric system [31]. An outstanding example of chimeric system
has been proposed by Knipe and co-workers [32], who dealt with the
oral release of siRNA targeting TNF-β, an inﬂammatory cytokine that is
a clinical target of inﬂammatory bowel diseases. The chimeric delivery
system consists of micro-gels (size< 30 μm) composed of poly(me-
thacrylic acid-co-N-vinyl-2-pyrrolidone) (PMANVP) crosslinked with a
trypsin – degradable peptide linker. PMANVP micro-gels contained
siRNA-loaded polycationic nanogels (2-(diethylamino)ethyl metacry-
late) (size≈ 120 nm) that proved to guarantee siRNA protection and
cells transfection. PMANVP matrix was designed to collapse around
nanogels to protect them from degradation in the stomach (pH 2–4),
while PMANVP swelling in the small intestine environment at
pH 6–7.5, allowed matrix degradation, due to the uptake of intestinal
ﬂuids containing trypsin. Consequently, nano-gels could be released
and internalized by cells, resulting in a considerable TNF-β knockdown
in a murine macrophage model.
Chimeric systems can be used for the systemic delivery of NABDs
too. Indeed, following injection administration, the NABD-vector
complex is supposed to circulate towards capillaries and micro-
vasculature structures (blood vessel diameter< 100 μm), cross the
blood vessel wall and ﬁnally reach the target cells. Thus, the NABD-
vector complex is required to move radially towards the vessel wall,
through a margination mechanism. D'Apolito and co-workers [33] ex-
perimentally showed that margination is due to red blood cells and
NABD-vector complexes interaction. The mentioned process is possible
whether complexes size spans in diameter range> 1 μm, with 3 μm
vectors better marginating than 1 μm sized particles. Accordingly,
nano-sized complexes have poor chances to get to the vessel wall.
However, nanocomplexes embedding into micro-vectors allows the
overall structure to reach blood vessel wall. Therein, nano-vectors can
be released, for example, by micro-vectors surface or bulk erosion.
3. siRNA delivery
3.1. Small interfering RNAs
During last years, the most commonly tested NABDs have been
siRNAs. These short double stranded RNA molecules approximately 22
nucleotides in length, are mostly of exogenous origin, being generated
from invasive nucleic acids such as viruses and transposons [34]. With
reference to the mechanism of the two siRNAs ﬁlaments (Fig. 2A),
mostly the antisense strand is uptaken by the cytoplasmic RNA-induced
silencing protein complex (RISC). The antisense strand drives RISC to a
target RNA via a perfect sequence complementarity to the target. Fol-
lowing binding, RISC mediates the degradation of the target RNA thus
resulting in the downregulation of gene expression. It is possible to take
advantage of this mechanism of action to generate siRNAs able to target
RNAs causing disease, as shown in many other works [35–38].
3.2. siRNA delivery problems
Despite the great siRNA therapeutic potential, their practical use is
limited by their chemical nature. Following systemic administration,
siRNAs encounter blood nucleases, which can rapidly degrade their
nucleic acid structure (Fig. 2B).
Moreover, siRNAs tend to be removed by the reticulo-endothelial
system, by kidney ﬁltration [39] and, depending on the sequence, to
activate the innate immune response [40]. Additional barriers to
siRNAs cellular uptake are represented by the vessel wall and the cel-
lular membrane, due to the electrostatic repulsion between the nega-
tively charged phosphate groups present on siRNAs and the negatively
charged surface of cellular membranes. Moreover, siRNAs cellular up-
take is diﬃcult due to its hydrophilic nature of that does not enhance
the crossing of the hydrophobic layer of the cell membranes.
The fraction of siRNAs that succeed crossing the cell membrane,
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further will face with cytosolic nucleases and then can reduce their
amount. Finally, siRNAs experience the problem of cellular traﬃcking
[41]. Depending on the mechanism of cellular internalization, siRNAs
can be uptaken by endosomes. At this stage, when conﬁned into these
intracellular vesicles, siRNAs cannot reach their targets and thus to
exert any biological eﬀect. Based on the abovementioned considera-
tions, the administration of naked siRNA results in negligible ther-
apeutic eﬀects.
3.3. Strategies to minimize siRNA delivery issues
Two main strategies can be employed in order to minimize the
delivery issues of exogenous siRNAs. The ﬁrst one consists of a chemical
modiﬁcation of siRNA structure to make these molecules more resistant
to degradation. The second strategy is based on the siRNA complexation
with synthetic engineered vectors to eﬀectively bind and protect
siRNAs and to allow their delivery to the target cells [42]. Frequently,
the two strategies are used in combination, even though some chemical
modiﬁcations may aﬀect siRNA eﬀectiveness.
The choice of the optimal delivery materials is not a trivial task
[12,34,42,43], with the net superﬁcial charge of the delivery carrier/
siRNA complex playing a key role. Anionic and cationic complexes
usually show good solubility/stability in the physiological environ-
ment, despite they exhibit some drawbacks. Anionic complexes cannot
transfect cells per se, due to the electrostatic repulsion with the nega-
tively charged cell membrane. Conversely, cationic complexes bind to
cell membrane towards strong electrostatic interactions, leading to non-
speciﬁc cellular uptake and cell toxicity if the positive charge is not
optimal [44]. On the other hand, neutral complexes tend to associate in
the physiological environment, resulting in a limited solubility. Thus,
the development of optimal delivery carriers requires a careful eva-
luation of diﬀerent parameters such as the surface charge density.
Besides providing for siRNA protection and targeting, the ideal de-
livery vector should be able to allow eﬃcient extravasation of the
siRNA. This feature is crucial for siRNA-vector complexes systemic
administration. Therein, the size of siRNA-vector complexes plays a
relevant role, as abovementioned for NABDs. It has been recently
showed that particles in the 1–3 μm diameter range [33] tend to loca-
lize closer to the endothelial layer (margination eﬀect) of the vessel,
compared to smaller particles. Thus, 1–3 μm particles localize closer to
the vessel fenestration, being more susceptible to extravasation com-
pared to smaller particles, which, alternatively, tend to localize in the
middle of the vessel. Despite this advantage, it should be considered
that particles bigger than 0.2 μm are readily scavenged non-speciﬁcally
by monocytes and the reticuloendothelial system, thus not be eﬃciently
uptaken by cells [45,46]. A possible solution may rely on the pre-
paration of microparticles able to undergo a disassembly, upon extra-
vasation, originating nano-metric particles. As previously introduced,
the preparation of micro-sized delivery systems containing nano-metric
particles can be included within the class of delivery strategies known
as “chimeric systems” [30,47]. This approach presents a dual ad-
vantage. First, micro-particles are easy to handle, to produce on large
scale and to store. Secondly, nanostructures are characterized by an
extremely high surface/volume ratio, with valuable drug payload eﬃ-
ciency. Polycationic polymers and lipids are most commonly employed
to form nanoscale vectors. On the other hand, microscale vectors en-
trapping nanoscale vectors usually consist of two/three dimensional
scaﬀolds or matrices mainly made by polymers.
The following sections will focus on the presentation of strategies
most commonly used to prepare nanoscale vectors, i.e. lipid and poly-
mers nanoparticles [48–52].
3.3.1. Lipidic nanoparticles
Lipid-based nanoparticles (LNPs) have been extensively used as
delivery systems for drugs and siRNAs, showing promising results both
in vivo and in vitro. LNPs have appropriate delivery characteristics as
their structure mimics cellular membranes, thus enhance the fusion
with the target cell. Moreover, LNPs can be easily loaded with several
cargo molecules.
3.3.1.1. Liposomes. Liposomes are spherical self-assembled vesicles,
deriving from synthetic or natural phospholipids containing aqueous
compartments (Fig. 3A). The polar heads of phospholipids interact with
the hydrophilic environment thus stabilizing lipids structure; in
contrast, the long phospholipid chains interact each other, forming
lipid layers in aqueous solution. Liposomes can be structured as
unilamellar or multilamellar lipid bilayers. Due to the amphiphilic
nature of phospholipids, these molecules can generate hydrophilic and
hydrophobic compartments in the same system, thus allow for both
hydrophobic and hydrophilic molecules (siRNA) hosting. Liposomes
present a low immunogenicity and are biodegradable [53].
3.3.1.2. Cationic liposomes. Positively charged (cationic) liposomes are
most frequently used for siRNA delivery. They can electrostatically
Fig. 2. (A) Schematic representation of siRNA cascade towards cytoplasmic RNA-induced silencing protein complex (RISC). The antisense strand siRNA ﬁlament is mainly up-taken by
RISC. The antisense strand can drive RISC to a region of perfect complementarity on the target RNA inducing its degradation. (B) siRNA metabolism throughout cellular mechanisms.
Before reaching its target, siRNA has to pass through a number of barriers, including the crossing of the vessel wall and the cellular membrane, as well as degradation from the
extracellular/cellular nucleases and endosomes.
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interact with the negatively charged siRNAs and allow an eﬃcient
molecule loading [43,54]. Additionally, cationic liposomes can
easily interact with the negatively charged cell membrane.
Sometimes, to further improve the ability to integrate with cell
membrane,
they are added with non-cationic lipids, such as DOPE
(dioleoylphosphatidylethanolamine) and DSPC (1,2-Distearoyl-sn-
glycero-3-phosphocholine). The positive surface charge is favourable
for siRNA binding, but it can cause the side interaction with negatively
charged serum protein such as albumin. In such a case, the negatively
charged serum protein can displace siRNA from the positively charged
liposome, thus signiﬁcantly reducing the amount of siRNA delivered to
the target tissue. The modiﬁcation of liposomes with the neutral lipids
such as cholesterol can contribute to overcome this limitation [55].
Moreover, cholesterol can be used also to bind other molecules such as
polyethylene glycol (PEG), a polymer able to improve the delivery
properties both in vitro and in vivo [53].
There are diﬀerent types of cationic liposomes for siRNA delivery,
such as monovalent cationic liposomes and multivalent cationic lipo-
somes. For instance, N-[1-(2,3-dioleyloxy) propyl]-N,N,N-trimethy-
lammonium chloride (DOTMA), 1,2-bis(oleoyloxy)-3-(trimethy-
lammonio)-propane (DOTAP) and 3β-[N-(N′N′-dimethylaminoethane)
carbamoyl]cholesterol (DC-Chol) are monovalent cationic lipids, char-
acterized by a high in vitro transfection eﬃciency [56].
Multivalent cationic lipids (MCLs), synthetized from monovalent
cationic lipids, exhibit an increased positive charge compared to
monovalent cationic lipids. However, they tend to be more toxic than
monovalent cationic lipids [57]. A widely used MCL transfection agent
is Lipofectamine (2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-
N,N-dimethyl-1-pro-paneammonium triﬂuoroacetate and dioleoyl-hos-
phatidylethanolamine in ratio 3:1 (DOSPA/DOPE 3/1)), which contains
the multivalent cationic lipid DOSPA. This mixture of lipids forms
multilayers structures with the siRNA being embedded between ad-
jacent lipid bilayers [58]. Lipofectamine can eﬃciently deliver siRNAs
to a broad range of cells, although they exert a signiﬁcant unspeciﬁc
cell toxicity. For example, siRNAs directed against the mRNAs of the
cell cycle promoting genes cyclin E and E2F resulted in a relevant in-
hibition of smooth muscle cells (SMC) proliferation. As SMC aberrant
proliferation is a key event in many coronary artery diseases [46,59],
the mentioned approach has the potential to minimize this pathological
event. Per se, the cationic liposome-mediated delivery of siRNAs to the
coronary wall is not suﬃcient to guarantee an eﬀective delivery. In this
case, the delivery of siRNA-cationic liposomes entrapped into gel matrix
has been proposed, in order to prevent the rapid wash out of siRNA
complexes due to blood ﬂow [60].
3.3.1.3. Stable nucleic acid lipid particles (SNALPs). Recently, stable
nucleic acid lipid particles (SNALPs) have been developed for siRNAs
delivery (Fig. 3B) [43]. SNAPLs are constituted by a lipid bilayer
containing the ionisable cationic lipid 1,2-dilinoleyloxy-3-
dimethylaminopropane (DLinDMA) or 2,2-dilinoleyl-4-(2-
dimethylaminoethyl)- [1,3]-dioxolane (DLin-KC2-DMA) in the inner
part, to allow the binding with siRNAs. Moreover, they contain PEG,
which can stabilize the complex and a neutral lipid, like DSPC or
cholesterol, which enhances the endosomal escape of the SNALP/siRNA
complex [61]. Thus, the structure of SNALPs is characterized by an
inner hydrophilic part, which allows the electrostatic binding with
siRNAs, while the external surface is nearly neutral. Appropriate
modiﬁcations in SNALPs, for example in the type and ratio of the
diﬀerent components, can extend the circulation time and minimize
complement system activation [53].
SNALPs delivery systems were for example used to encapsulate a
Fig. 3. Schematic representation of the main nanoscale vectors: (A) liposomes, (B) stable nucleic acid lipid particles (SNALPs), (C) lipidoids and (D) solid lipid nanoparticles. (A)
Liposomes, due to the amphiphilic nature of their phospholipids, can generate hydrophilic and hydrophobic compartments in the same system, thus allowing for both hydrophobic and
hydrophilic molecules (siRNA) hosting. (B) SNALPs are characterized by an inner hydrophilic part, which allows the electrostatic binding with siRNAs, and an outer part that is nearly
neutral. (C) Lipidoids contain a polar and ionisable core, where siRNA can bind, and an external hydrophobic layer. (D) SLN are derived from nano-emulsions where the oil emulsion
component is replaced by a solid lipid dispersed in a surfactant solution; chemical modiﬁcations are required to allow the incorporation of the hydrophilic siRNA into SLN.
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COP9 Signalosome Subunit 5 (CSN5) siRNA [62]. CSN5 is the catalytic
center of the COP9 Signalosome that is involved in the control of pro-
teolysis via the ubiquitin proteasoma pathway. CSN5 seems also to act
as transcriptional coactivator for MYC and TGFβ1, gene products in-
volved in the control of proliferation, apoptotic cell death and hepa-
tocellular carcinoma (HCC) progression. This delivery system sig-
niﬁcantly inhibited tumor growth in an orthotopic mouse model of HCC
[62].
3.3.1.4. Lipidoid nanoparticles. Lipidoid nanoparticles are made up of
synthetic lipids obtained by the chemical combination of alkyl-amines
with alkyl-acrylates containing carbon chain tail of variable length [63]
(Fig. 3C). The particles containing the lipidoid have a polar and
ionisable core, surrounded by hydrophobic carbon tails. The particles
can also contain cholesterol and PEG, two types of molecules that can
enhance particles stability and delivery eﬃciency [58]. In addition,
their simple synthetic protocol allows the production of a considerable
amount of diﬀerent particles, which can be tailored to any diﬀerent
delivery purpose. For example, a siRNA embedded into lipidoid-based
nanoparticles was used to downregulate β1 and αν integrin subunits in
the hepatocytes of a xenograft mice model of HCC [64]. β1 and αν
integrins are relevant extracellular matrix receptors involved in many
cellular processes. Moreover, they play critical biological roles both in
normal liver and in HCC tumor cells. Integrin silencing had, as major
outcome, an extended morbidity-free survival of HCC tumor-bearing
mice [64].
3.3.1.5. Solid-lipid nanoparticles. Solid-lipid nanoparticles (SLN) are
novel siRNAs carriers derived from nano-emulsions where the oil
emulsion component is replaced by a solid lipid dispersed in a
surfactant solution (Fig. 3D). The loaded molecules are incorporated
in the solid lipophilic matrix. SLN, solid at room temperature, are
stable, non-cytotoxic, present a large surface area and can eﬃciently
protect the encapsulated molecules [65]. However, they show some
disadvantages such as the low molecules loading capacity and the
possible expulsion of the incorporated molecules during storage. The
chemical nature of the solid-lipid matrix determines the loading
capacity, as well as the type of molecule to be loaded [66]. SLN
usually contain a combination of triglycerides, partial glycerides, fatty
acids, steroids and waxes. In order to decrease cytotoxicity and immune
responses, SLN can be prepared using physiological lipids present in the
natural low density lipoprotein (LDL) such as cholesteryl ester,
triglyceride, cholesterol, DOPE, and DC-cholesterol [67]. Lipids found
in the natural high-density lipoproteins (HDL) represent an alternative.
Overall, chemical modiﬁcations are required to allow the incorporation
of the hydrophilic siRNA [68]. An example of siRNA delivery by SLN
has been reported by Jin J. et al. [69]. Considering that c-mesenchymal-
epithelial transition (c-MET) is a signalling receptor for hepatocyte
growth factor, SLN were reconstituted from natural components of
protein-free LDL and further conjugated to PEGylated c-Met siRNA.
Inappropriate c-Met activation relates to diﬀerent form of human
tumours including glioblastomas (GBMs). The latter is the most
frequent and malignant form of brain tumor, with limited treatment
options due to the blood-brain barrier. In orthotopic U-87MG xenograft
tumor model of GBM, intravenous administration of the complex
signiﬁcantly inhibited c-Met expression and suppressed tumor growth.
No major signs of systemic toxicity were observed in mice.
3.3.2. Polymers
Polymers are solid and biodegradable molecules widely employed
for siRNA delivery. Many diﬀerent polymers have been tested so far,
such as Chitosan (CH), Polyethylenimine (PEI), PEG, α,β-poly(N-2-hy-
droxyethyl)-D,L-aspartamide and Inulin-derived polymers.
CH is a polymer characterized by low toxicity, high biocompatibility
and biodegradability [12]. CH is derived from chitin, has a carbohy-
drate backbone characterized by two types of repeating residues, 2-
amino-2-deoxy-glucose (glucosamine) and 2-N-acetyl-2-deoxy-glucose
(N-glucosamine), linked by (1–4)-β-glycosidic linkage. Furthermore,
CH has a positive charge, due to the presence of positively charged
amino groups present in its structure, thus, it can easily and eﬃciently
bind negatively charged molecules such as siRNAs. On the other hand,
CH has some disadvantages such as the low transfection eﬃciency and
low solubility, which can be prevented through the conjugation with
other molecules such as PEI, PEG, Poly (amidoamine) (PAMAM) den-
drimers. As an alternative, CH physicochemical and biological proper-
ties can be improved by modulating the deacetylation rate and/or
modifying the molecular weight [70]. In order to solve CH drawbacks,
another approach involves the use of synthetic polymers (e. g. PEI).
Such a polymer contains repeating units composed of an amine group
and two aliphatic CH2-CH2 spacers. It can exist both in linear and
branched forms. It is one of the most used cationic polymers, even
though it tends to be more toxic than natural polymers [71]. Usually,
PEI with high molecular weight has higher cytotoxicity compared to
low molecular weight PEI, despite its transfection eﬀectiveness. To
decrease toxicity, PEI can be chemically modiﬁed, such as the addition
of hydrophilic and hydrophobic segments or cell/tissue-speciﬁc ligands
[72]. As previously described for CH, PEI easily binds negatively
charged molecule such as siRNAs. Moreover, PEI favours siRNA escape
from endosomes, thanks to its “proton sponge eﬀect” [73]. Finally, li-
posome coating with PEI results in an increased liposomes circulatory
time [74], thus improving systemic delivery.
PEG is a polymer of ethylene oxide monomers considered to be non-
toxic and safe [75,76]. It is widely used because of its solubility in
aqueous environment and organic solvents. PEG addition (PEGylation)
to deliver particles reduces toxicity and stabilizes the particles, as it is
the case of PEGylated liposomes where PEG is added into the liposomal
bilayer [77]. PEG is also used to bind speciﬁc ligands to be ﬁxed on the
liposome surface [78].
For instance, a copolymer based on α,β-poly(N-2-hydroxyethyl)-D,L-
aspartamide (PHEA) bearing positively chargeable side oligochains,
with diethylamino ethyl methacrylate (DEAEMA) as monomer has been
developed [79]. The PHEA-DEAEMA polymer was able to eﬃciently
form complexes with siRNA. Moreover, it demonstrated to be stable in
liquid ﬂuids and protected siRNA without being signiﬁcantly cytotoxic
in the HCC cell line HuH-7. The copolymer was loaded with an anti
E2F1 siRNA and tested in JHH6. E2F1 is a transcription factor pro-
moting cell proliferation that plays an important role in the growth of
HCC cells [28]. A signiﬁcant down regulation of JHH6 cell growth was
observed, in addition to a reduction in siRNA target.
As an alternative polymer for HCC cell delivery, a siRNA delivery
system based on inulin (Inu) was reported. This is an abundant and
natural polysaccharide functionalized for the speciﬁc requirements of
siRNA delivery by conjugation with diethylenetriamine (DETA) re-
sidues (Inu-DETA) [80]. Inu-DETA copolymers can eﬀectively bind
siRNAs, are highly biocompatible and, in the HCC cell line JHH6, can
eﬀectively deliver functional siRNAs. The Inu-DETA particles loaded
with a siRNA anti E2F1 [28], eﬀectively reduced the levels of E2F1 and
the proliferation of JHH6. Moreover, the uptake and traﬃcking me-
chanisms, mainly based on micropinocytosis and clatrin mediated en-
docytosis, allowed a triggered release of siRNA within the cytoplasm of
JHH6.
The abovementioned examples clearly indicate how cationic copo-
lymers can bind siRNAs via electrostatic interaction, thus forming
complexes able to promote cellular uptake and signiﬁcantly improve
the half-life. However, polymers can be also used in the form of micelles
for delivery purposes. Micelles are spherical structures containing
simple units (unimers) oriented with the hydrophobic tail towards the
inner part of the micelles and the hydrophilic heads against the external
shell (Fig. 4). Unimers can be generated conjugating cationic polymers
with stearic acid (SA), a saturated fatty acid with an 18-carbon chain.
For example, CH polymer does not self-assembly into micelles; never-
theless, following the conjugation with stearic acid (SA), CH polymer
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can form micelles. This example demonstrates good plasticity of poly-
mers and their derivatives to prepare siRNA delivery systems [81].
Other example of cationic polymer able to form micelles in solution is
PEG and poly(propylene sulﬁde) [82,83].
4. Plasmid, gene and probiotic delivery
Considering drug-based treatments are limited to treat symptoms,
gene delivery emerged as a very promising method for the treatment (or
elimination) of the causes associated to a broad range of diseases re-
lated to genetic factors [84]. This approach relies on the eﬀective de-
livery and transfer of genes into speciﬁc cells to alter the expression of
the existing ones. Theoretically, it should either cure the disease or, at
least, slowdown its progression [84]. There are two main components
in the system: the carrier (i. e. gene delivery vector) and the therapeutic
agent (i. e. genetic material). The delivery system should be able to
carry, protect and deliver the genes in a safe and eﬀective system to a
wide range of diﬀerent cells [85]. Although viral based vectors are
extremely eﬃcient carriers to deliver genes, several drawbacks asso-
ciated to their high cost, diﬃculties in large scale production and safety
issues (e.g immunogenicity, tumorigenic mutations) have driven the
attention to other technological alternatives. In this context, during the
last decades, a lot of attention has been focused on the development of
eﬃcient non-viral vectors for gene delivery. Despite the low eﬃciency
compared to viral vectors, these systems present several important
advantages, such as low immunogenicity, absence of endogenous virus
recombination, low production cost, easy implementation in large scale
[86,87].
As previously discussed, within the non-viral systems class, cationic
polymers have received a growing interest due to the possibility to
easily tune their structure and characteristics (e.g molecular weight and
composition) in order to enhance the performance of the gene delivery
system [88]. The positive charges of the cationic polymers interact
electrostatically with the negative charges of the gene material, leading
to the formation of complexes known as polyplexes. Since the pioneer
work of Vaheri and Pagamo, in 1965, that proposed the use of dextran
functionalized with diethylaminoethyl groups [89], an enormous li-
brary of cationic polymers have been suggested for gene delivery, such
as chitosan [90,91], poly(L-Lysine) (PLL) [92], poly(ethylenimine) (PEI)
[93], poly [(2-dimethylamino) ethyl methacrylate] (PDMAEMA) [94]
and poly(β-amino ester) (PβAE) [95]. Despite branched PEI [93]
(Mw= 25,000 g ∙mol−1) has been considered as the “gold standard”
due to the high transfection eﬃciency, its high toxicity seriously
compromises its use [96] (Fig. 5).
Overall, two main problems are associated to the polymer-based
systems: minor eﬃciency due to the deﬁcient capacity to overcome
some extra- and intracellular gene delivery obstacles (e.g diﬀusion to
the endothelial membrane, endosomal escape, unpacking among
others); and cytotoxicity [97]. These issues have been mitigated using
diﬀerent approaches that include: the use of poly(ethylene glycol)
(PEG); introduction of hydrophobic segments [97]; and the functiona-
lization of polymers with moieties such as sugar molecules, antibodies,
growth factors, etc. [87].
Despite the remarkable advances registered over the last decades on
gene therapy, the levels of eﬃciency are very unsatisfactory to turn
their clinical usage a routine. A promising approach to overcome this
limitation involves the use of stimuli-responsive polymers that can
change their physico-chemical characteristics upon the application of a
speciﬁc stimulus. In the gene therapy area, these stimuli can be en-
dogenous like enzyme concentration, pH, redox potential, or exogenous
such as temperature, light and ultrasounds. The remarkable feature of
this class of polymers relies on the possibility to rationally adapt the
physical/chemical characteristics of polyplexes during their path to
maximize their eﬃciency. The binding capability of the cationic seg-
ment should be high to aﬀord dense and stable polyplex, while during
the unpacking step weaker bindings are required [98,99]. Therefore,
the use of stimuli-responsive polymers can be a very eﬀective approach
to tailor the properties of polyplexes in the diﬀerent environments both
outside and inside the cell. Aiming to explore the potential of these
smart systems, several carriers have been used in gene therapy
[100–102]. PDMAEMA is a thermoresponsive and pH-responsive
polymer, being one of the most used systems in gene delivery, able to
easily complex with DNA [94].
Reversible Deactivation Radical Polymerization (RDRP) methods
brought an outstanding toolbox of techniques that allows to synthesize
tailor-made polymers with controlled composition, architecture, mole-
cular weight and active chain-end functional groups [103]. Advances
on “click” chemistry techniques [104] as 1,3-dipolar azide-alkyne cy-
cloaddition (CuAAC) [105] and/or thiol-ene [106] reactions has
opened important routes to the synthesis of novel block copolymers and
in the functionalization with diﬀerent moieties (e.g proteins, sugars) to
well-deﬁned polymer backbone.
Nowadays, it is possible to establish precise structure/properties
relationships for the diﬀerent polymers due to the ability to control
their composition, structure, and functionality. Atom Transfer Radical
Polymerization (ATRP) [103,107] and RAFT (Reversible Addition
Fragmentation Transfer) [108–110] are the most used ones to develop
block copolymers for gene delivery. Several recent reviews have high-
lighted the important progresses achieved with these two advanced
polymerization techniques in biomedical applications and gene delivery
[111,112]. Controlled molecular architectures in terms of chain to-
pology [103,108] (cycles, stars, combs, brushes), composition
[103,108] (block, graft, alternating, gradient copolymers), and func-
tionality are now easily accessible for most type of monomers used to
aﬀord stimuli-responsive structures. Star polymers, due to the higher
ability of forming spherical polyplexes, which enhances the inter-
nalization in the cell, have received particular attention [113]. Indeed,
several contributions have shown promising results for stars regarding
transfection eﬃciency when compared to their linear or randomly
branched counterparts [114–116].
The simultaneous development of the polymer synthesis strategies
over the next years will allow the preparation of new block copolymers
with innovative sequential addition of new monomers. Consequently, it
can be easily envisaged that there will be the appearance of the new
cationic block copolymers rationally designed to overcome the afore-
mentioned limitations (e.g biological barriers) leading to broad use of
non-viral vectors in clinical practice.
Surfactants, such as polymers, are excellent candidates for non-viral
methods in gene delivery. As previously discussed, depending on
Fig. 4. Schematic representation of a polymeric micelle. Micelles are spherical structures
containing simple units (unimers) oriented with the hydrophobic tail towards the inner
part of the micelles and the hydrophilic heads over the external shell; siRNA can be
hosted in the hydrophilic region of micelles.
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surfactant architecture, they can self-assembly into diﬀerent structures
and work as eﬃcient nano-compartments for gene delivery [117]. For
this purpose, many synthetic surfactants or lipids have been designed to
increase the performance of cellular uptake, transfection eﬃciency
[118] and to enhance the solubility of hydrophobic molecules, making
them suitable for parenteral administration. An extensive number of
contributions encompassing the advantages of surfactant based gene
delivery systems are available in the literature [119–124].
Surfactant based nanoparticles are already been used to treat ge-
netic and acquired disorders [125] due to their demonstrated high
ability to condense and deliver nucleic acid molecules [126]. As men-
tioned in the previous section, the stabilization of the vectors composed
of surfactant or lipid aggregates can be achieved by the addition of
diﬀerent additives such as cholesterol to increase the packing of
phospholipid [127,128], or polyethylene glycol (PEG) to protect na-
noparticles from the immune system [129].
A large range of reports suggests the use of cationic surfactants as
vectors for the delivery of nucleic acids [126,130,131]. Their success is
related to easy synthetic pathways, as well as an eﬃcient condensation
and delivery of anionic nucleic acids through electrostatic interactions.
The cellular uptake of the nucleic acid-cationic surfactant com-
plexes is driven by the disruption of the endosomal membrane due to
the ion pair of the cationic surfactant and anionic lipids within the
endosome membrane [132]. Regarding the structure, the complexes of
the cationic surfactants and anionic phospholipids are usually arranged
as inverted hexagonal phases, which are supposed to promote the re-
lease of the plasmid from the endosome into the cytoplasm [132].
Gemini are another class of very promising type surfactants that has
been highly eﬀective in delivering genetic material to cells. These
systems show a very low critical micelle concentration, which allows a
lower surfactant amount to achieve the same encapsulation capability
[117].
Polymers and surfactants are able to encapsulate genes and drugs, as
well as further cargo of interest for the treatment of diﬀerent diseases or
health problems, such as probiotics. Indeed, there have been con-
siderable eﬀorts in understanding the therapeutic eﬀects of probiotic
bacteria for diﬀerent types of health issues, ranging from gastric dis-
eases to atopic dermatitis [133]. Probiotics are living microorganisms
with beneﬁcial health eﬀects to the host by replenishing natural gas-
trointestinal microbiota. The eﬀectiveness of probiotics intake in some
clinical cases has been already recognized e.g. in acute gastroenteritis
[134]. About 1014 viable probiotic cells have been estimated to be
potentially active against harmful bacteria in the gastrointestinal tract
of an adult. Their balance depends on the diet of the host, medication
intake, hygiene habits and diseased state [135]. Recent evidences
highlight a remarkable role of the gut microbiota in the susceptibility to
diﬀerent disease phenotypes, which are often followed by dysbiosis,
and are a major public health concern, e.g. obesity, diabetes and in-
testinal syndromes [136–138]. In this context, probiotics exhibited a
pivotal inﬂuence in the modiﬁcation of the gene expressions, which are
involved in immunomodulation, nutrient absorption, suppression of
pathogens, energy metabolism and intestinal barrier function such as
stimulation of epithelial cell proliferation or induction of mucin se-
cretion [133,139–141].
The positive health beneﬁts provided by these probiotic agents are
essentially strain- and disease-dependent. Moreover, designing a de-
livery vehicle, able to overcome the physiological variations (i.e. tem-
perature, pH, ionic strength, etc) with an eﬃcient approach and
without any harmful eﬀect on tissues, is a challenging task. As pre-
viously discussed for the gene delivery, several (but rather similar)
barriers can delay or prevent the delivery of probiotic bacteria in a safe
and eﬀective way. Probiotics are often administered orally and, in such
case, the cells are primarily microencapsulated in order to protect them
from the harsh conditions of the gastrointestinal passage, i.e. low pH,
presence of bile salts and enzymes. The microcapsules are usually
formed by extrusion, emulsion, spray- and freeze-drying [142,143].
Polysaccharides (alginate, chitosan, gellan and xanthan gums) and milk
proteins are among the most commonly used encapsulating agents
[144]. From a formulation point of view, alginate-based materials have
been the most explored, due to their biodegradability, very good cy-
tocompatibility and mucoadhesive properties. Nevertheless, a new
thread on systems for the encapsulation and delivery of probiotics is
focused on their ability to provide for “smart” responses, according to
the changes in the physiological environment [145]. For instance, it is
possible to develop pH- or thermo-sensitive delivery systems, triggered
by precise changes on physiological parameters [146]. As previously
mentioned, sugar-based biopolymers have been in the spotlight, thanks
to their biocompatibility and availability reasons [147]. The use of new
tailor-made polymers with smart responses (e.g. using the aforemen-
tioned RDRP methods) reveals as a promising ﬁeld to be explored in the
Fig. 5. Schematic examples of cationic polymers
used as nonviral gene delivery vectors. Chitosan
is a cationic polysaccharide obtained from the
alkaline deacetylation of chitin. Poly(L-lysine) is
plenty of ɛ-amino groups, being able to condense
genetic material. Linear poly(ethyleneimine) is
composed exclusively by secondary amines and
was the second gene transfection agent dis-
covered, after poly(L-lysine). Branched poly
(ethyleneimine) has primary, secondary and ter-
tiary amines in its structure and it is considered
the ‘gold standard’ of the gene transfection
agents. Poly(β-aminoesters) are able to self-as-
semble genetic material and form positively
charged nanoparticles. Poly(2-dimethylami-
noethyl methacrylate) is composed by tertiary
amines and has a transfection eﬃciency similar
to branched poly(ethyleneimine) and
Lipofectamine™. (For interpretation of the refer-
ences to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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near future and will allow the use of probiotics in the treatment of
diﬀerent health issues.
5. Proteins and growth factor delivery
Smart biomaterial approach is one of the fastest growing segments
for the treatment of high impact diseases, such as cancers, dietary-re-
lated disorders, ischemic diseases and dramatic inﬂammatory re-
sponses. It is set to expand over the near future, fuelled mainly by the
unmet requirements from the market for less invasive and more suc-
cessful treatments, in particular in the key areas of inﬂammatory pa-
thological conditions. The convenience and home use appeal for pa-
tients is the main driving factor of this industrial branch.
In this context, the most high impact cause of death and/or dis-
ability in developed countries refers to enzyme and protein disorders
and related consequences [148,149]. Currently, aﬀected patients
cannot rely on a wide variety of surgical and medical options; this
condition involves an urgent need of possible treatment alternatives,
with a main challenge lying in the decrease of side eﬀects and speciﬁc
tailoring of the therapeutic approach. In detail, a promising strategy
concerns the study of key pathological signalling mechanisms and re-
lated pathways involved in the switch control between normal and
aberrant conditions. The rationale behind such an innovative perspec-
tive is on stage for the development of more eﬀective chances to ther-
apeutically tune the inﬂammatory pathways. An important target dis-
order where inﬂammatory processes are actively incorporated deals
with cancers: therein, biosensing approaches, such as tuning and si-
lencing of protein and enzymatic activity, as well as regulation of small
molecule signalling are clever strategies with a huge potential for im-
pact of people's daily life, towards the industrial nanobiotechnology
sector growth. Over the years, nanotechnology has developed con-
siderably as a result of novel technological discoveries, in the area of
smart materials and related application. One area in bionanomaterials
that oﬀers great potential is represented by self-assembly approaches,
thanks to their easy strategy for preparation and suitability for biotech
engineering tailored modiﬁcation. Self-assembly is the process of inter-
and intra-molecular bonding through van der Waals forces, ionic in-
teractions, H-bonding or hydrophobic interactions, which results in the
formation of particularly formed structures, that can either form col-
loidal crystals or particle cluster among others. The intrinsic mobility of
self-assembled complexes leads to ordered nanostructures upon equi-
libration between aggregated and non-aggregated states, thus providing
a number of interesting properties such as error correction, self-healing,
and high sensitivity to external stimuli. These structuring features are
nowadays well understood and can be ﬁnely controlled in order to in-
troduce and tune functional properties of self-assembled nanomaterials
used for a wide range of applications.
Polymer-based self-assembled nanostructures, as well as organic
nanomaterials (e. g. carbon nano-materials [150]) have great potential
as drug delivery vehicles for invasive cancers, mainly as a result of their
good biocompatibility [151] and natural degradation/resorption path-
ways [152]. On the other hand, self-assembled hydrogels, composed of
biocompatible and amphiphilic polymer conjugates, have been shown
to exhibit prolonged circulation in blood and preferential accumulation
when administrated either in vitro or in vivo. From a targeted respon-
siveness point-of-view, cancers and aberrant conditions, demonstrated
to be associated to low pH [153]. Thus, pH proved to be an excellent
trigger for targeted cancer release carriers and further silencing of key
pathological mechanisms therein involved. Another target involves
small molecule changes in the cellular environment, such as Reactive
Oxygen Species (ROS) [154] and formation of small amines/alcohol
[155].
Besides, intercommunication between cells is mainly driven by
growth factors, polypeptides which can modulate cellular behavior
related to diﬀerentiation, proliferation and their ability to synthesize
extra cellular matrix (ECM), by speciﬁcally targeting receptors on the
cell surface [156]. Most biological processes are initiated by self-as-
sembly reactions in the body. For example, assembly of amino acids to
peptides to speciﬁc secondary, tertiary and quaternary structures that
give rise to structural and functional proteins. From a material point-of-
view, this naturally occurring phenomenon can be recapitulated arti-
ﬁcially through spontaneous and random assembly of naturally occur-
ring proteins or with a bottom-up approach by incorporating functional
sequences, which dictate a speciﬁc biological response. In this context,
hydrogel systems have been successfully employed for growth factor
delivery and regenerative purposes, thanks to their ability to ensure a
controlled cell migration [157,158]. Moreover, as previously discussed,
hydrogels are widely applied for drug delivery purposes, as they mimic
the natural ECM [159,160] and allow a dual responsive drug release,
oﬀering the advantage of incorporation of further supramolecular
structure, such as liposomes and further micro/nano carriers.
For instance, the peptide sequence (Pro-Lys-Gly)4(Pro-Hyp-Gly)
4(Asp-Hyp-Gly)4 simulates the collagen self-assembly into a ﬁbrous
structure, which eventually triggers a hydrogel formation [161]. Simi-
larly, α helical peptides [162], β sheet peptides [163], β hairpin pep-
tides [164], amphiphilic peptides [165] and multi-domain peptides
[166,167] can lead to self-assembled hydrogels based on the chirality
and nature of the aminoacidic side chains. As a result, the supramole-
cular hydrogels may vary in their physico-chemical properties such as
stiﬀness, porosity and degradation properties.
The physico-chemical properties of hydrogel platforms play an im-
portant role in controlled delivery of bioactive factors or cells with a
therapeutic potential. A recent study has shown the use of a three-di-
mensional, self-assembled type-I collagen microgel in modulating an-
giogenic responses of human mesenchymal stem cells [168]. Such ECM
based microniches also help in promoting phenotypic changes by mi-
micking the signature matrix microenvironment of the predominant
cell population in the tissue [169,170]. Design of self-assembling pep-
tides using phage display with high aﬃnity to growth factors have been
utilized for spatio-temporal release of growth factors such as BMP-2
(YPVHPST) and TGF-B1 (LPLGNSH) for cartilage and bone regeneration
[171]. Stimulus responsiveness property has also been incorporated in
self-assembling hydrogels, where degradation is triggered in presence
of an enzyme or reactive species as catalyst. The self-assembly of such
multi-domain peptides allows greater control on ﬁber length and dia-
meter, gelling and viscoelastic properties due to its modular design. K
(SL)3RG(SL)3K-GRGDS is one example of a MMP2 cleavage speciﬁc
peptide which undergoes the proteolytic degradation by collagenase IV
[166]. For drug delivery, peptide amphiphiles loaded with therapeutic
drugs self-assemble into ﬁbrous nanostructures that disassembles and
releases the drug upon enzymatic phosphorylation of the serine residue
[172]. However, in vivo it becomes increasingly challenging to predict
the local concentration of reactive enzymes. Hence, peptide self-as-
sembling strategies incorporating ester groups, which hydrolyze in a
more controlled manner than enzymatic reactions are favourable [173].
Self-assembled hydrogels made from functional extracellular matrix
components have the advantage of achieving better biological re-
cognition in a 3D tissue like environments with high ﬁdelity. But the
complexity, lack of control of the self-assembly process and variation
from batch to batch may aﬀect reproducibity. However, a semi syn-
thetic approach in designing peptide sequences known to inﬂuence a
biological function such as diﬀerentiation, maintenance of stemness or
inﬂuence cellular secretome can be easily fabricated or coupled to a
polymeric framework to match the physical properties of the tissue.
This approach will endorse the need for designing a customised 3D
hydrogel with tunable mechanical and biochemical features using
functional recognition sequences. Another perspective, which has been
thoroughly investigated, involves spherical microgels, an interesting
bridging among macro-hydrogels and spherical microcarriers
[158,174]. They can be deﬁned as microscale hydrogels, oﬀering a
higher surface to volume ratio, compare to macroscale hydrogels. This
unique feature enhances both microgels stability and their integration
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within the local tissue mass transport, by decreasing the bulk resistance
[175,176].
In a size and structural complexity decreasing progression, soft self-
assembling frameworks for protein delivery can be encompassed by
catanionic vesicles, colloidal hollow structures, based on pairing of
oppositely charged ionic amphiphiles. In detail, the abovementioned
amphiphiles easily self-aggregate [177] into multi-walled vesicular
structures [178]. Vesicles are of increasing interest in the biotechno-
logical ﬁeld [179,180], mimicking biological membranes and their
compartmentalization features [181]. Moreover, triggering factors for
these structures involve salt/co-solutes addition, chain length and
temperature, able to provide to multi-to-unilamellar transition and thus
a controlled therapeutic release [182]. On the other side, liposomes
oﬀer another ‘soft’ alternative for tunable compartmentalization and
biological responsive protein delivery.
Microspheres and hollow spheres are an additional tool for tailored
delivery of proteins and growth factors, which have been extensively
studied. Both synthetic (i.e. polyethyetylene glycol-PEG and poly-
dimetylacrylamide-PDMA) and natural based polymers have been em-
ployed in their fabrication [183,184]. Diﬀerent strategies for their
production were proposed, such as emulsion, sacriﬁcal template
coating, chemical binding. Furthermore, ECM mimicking motifs allow
the speciﬁc targeting of cellular proteins: this peculiar hallmark pro-
vides these reservoir systems with excellent performances and targeting
properties, for growth factors delivery [185,186].
Still keep on decreasing the available protein vehicle systems, there
is considerable interest for carbon nano-onion [150]. These multi-shell
fullerene structures pertain unique physicochemical properties of, such
as ultra-small size, large surface to mass ratio, high ﬂexibility and
capability to be complexed (either covalently or non-covalently) with
bioactive molecules, including small proteins like enzyme binding
moieties [150] (Fig. 6).
6. Synthetic therapeutics delivery
6.1. Challenges of small molecules in drug delivery
Over the last twenty years, the main trend in pharmaceutical re-
search was driven towards a growing interest in macromolecular
therapeutics [187]. Nevertheless, most of the bioactive molecules still
belongs to the class of small molecules under 500 Da. For instance, in
cancer research, almost 75% of these therapeutics derive from synthetic
sources [188]. The major issue of small molecule therapeutics is re-
presented by the toxic side eﬀects of high doses, due to an overall poor
biodistribution and rapid clearance [189]. Moreover, when a low
invasive and high patient friendly administration route is chosen, such
as the oral approach, additional factors can inﬂuence and reduce the
therapeutic eﬃcacy of the majority of Active Pharmaceutical In-
gredients (APIs) with poor solubility and low permeability in gastro-
intestinal environment [190]. Besides solubility issues of hydrophobic
compunds, a larger group of drugs are susceptible to several biochem-
ical barriers, such as enzymatic attack, hydrolysis, degradation in the
low gastric pH, unspeciﬁc endocytosis of the extended mucosa surface
[191], pre-systemic metabolic pathways [192], intracellular bio-
trasformations [193] and plasma proteins complexation and recogni-
tion by the cells of the mononuclear phagocyte system [194].
Nowadays, the low bioavailability still represents a concrete
issue:> 90% of active compounds discovered and approved since 1995
belong either to class II or IV in the standard of Biopharmaceutical
Classiﬁcation System (BCS) [195]. Several strategies were developed to
enhance both solubility and permeability of APIs. These approaches
include the modiﬁcation of both physical and chemical properties of the
API [196]. The modiﬁcation of physical characteristics is mainly fo-
cused on micronization techniques [197,198] reduction of crystal sizes,
amorphization and stabilization of such solid dispersions [199,200].
Recently, further eﬀorts have been focused on the development of
speciﬁc organs and tissues targeting, while improving drug perme-
ability on speciﬁc diseased cell targets.
6.2. Lipid based-nanovesicles
As previously mentioned, lipid based nanovesicles (LNVs) are de-
ﬁned as spherical vesicles constituted by a bilayered lipid membrane. In
a size-driven perspective, these colloidal carriers can be divided into
small unilamellar vesicles (SUVs, with diameter< 200 nm and single
bilayer membrane), large unilamellar vesicles (LUVs, diameter ranging
200–1000 nm, single bilayer membrane), giant unilamellar vesicles
(GUVs, diameter> 1000 nm, single bilayer membrane), multilamellar
vesicles (MLVs composed by concentric vesicles, or multiple concentric
bilayers) and multi vesicular vesicles (MVVs, composed by multiple
vesicles conﬁned inside a larger one). Fig. 7 groups the diﬀerent types
of nanovesicular systems, with increasing size characteristics. Since the
ﬁrst LNV proposed by Gregoriadis in 1974 [122], a large number of
nanovesicicular systems were developed. Such an impressive success is
due to their ability to incorporate functional biomacromolecules on the
lipid bilayer, proposing as smart, ﬂexible, stimuli responsive systems.
Key features of these colloidal carriers involve the API encapsulation
eﬃciency (EE), the particle size distribution and the z potential.
Over lipidic nanovesicles class, liposomes were the ﬁrst discovered
structures, composed by natural phospholipids membranes in the form
Fig. 6. Schematic representation recapitulating platforms
for protein/growth factor delivery. Scaﬀold size is de-
creasing clockwise: (A) hydrogels, characterized by macro-
crosslinks, (B) microgels, composed by the interconnection
of microparticles, (C) multilamellar vesicles, colloidal
hollow structures ranging in the micron size, (D) liposomes,
soft lipidic-based nanocontainers, (E) hollow spheres, with
tunable size, from 100 nm to the micro-range and (F)
carbon nanonions, carbon based structures, spanning
within the 10 nm average diameter.
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of SUV and MLV. Nowadays, further in-depth researches explored the
use of many synthetic phospholipids like phosphatidylglycerol, phos-
phatidylethanolamine, phosphatidylcholine and phosphatidylserine
[201]. The ﬁrst method developed for the encapsulation of hydrophilic
compounds refers to the thin layer hydration (TLH), characterized by a
very low EE due to the highly non-favored partition of hydrophilic
molecules inside the vesicle cavity versus the surrounding aqueous
medium. Further methods involved the combination of TLH with other
approaches to enhance the EE of hydrophilic molecules: reiterated
freeze–thaw (FT), reverse phase evaporation (REV) and dehy-
dration–rehydration of empty vesicles (DRV).
The FT method allows the spontaneous MLVs disruption by the
water ice crystals produced in the freezing process, leading to the
fabrication of SUVs. The EE can be modulated by tuning the FT cycle
rate, the aqueous solute and lipid concentrations. Additional extrusion
steps after FT have shown to improve the size distribution, such as the
encapsulation of the hydrophilic drug itopride in liposomes [202]. On
the other hand, multiple FT cycles can increase liposome diameter and
polydispersity, when liposome components are highly susceptible to
salt concentration (i.e. egg phosphatidylcholine) [203].
Reverse phase evaporation method (REV) is another approach to
encapsulate small hydrophilic drugs. Therein, the lipids are dissolved in
an organic phase and further incorporated in an aqueous phase with the
drug. The obtained emulsion is subsequently treated with evaporation-
hydration cycles, leading to the formation of liposomes, mainly LUVs
with large EE. For example, the addition of the REV step to TLH in-
troduced an EE increase in the case of sumatriptan succinate [204].
Conversely the utilization of REV can result in a decrease of hydro-
phobic drugs encapsulation eﬃciency, compared to TFH, as in the case
of acetazolamide, inside multilamellar vesicles [205] and ketoprofen-
hydroxypropyl-β-cyclodextrin complexes included into large uni-
lamellar vesicles [206]. Liposomal vesicles can be fabricated by means
of a dehydration–rehydration method (DRV), adding a buﬀer to the thin
ﬁlm and further lyophilize. The solid pellet is then rehydrated with the
drug solution. Compared to conventional TFH, DRV produced a high
drug/lipid ratio in the case of vancomycin [207], with an impressive
increase of EE (30 and 130 fold), for both non-decorated and pegylated
liposomes, respectively. Recent reviews discussed innovative methods
for liposomes fabrication [208–210], including microﬂuidics
[211,212], compressed/supercritical ﬂuids for the incorporation of
both hydrophilic and lipophilic drugs into the vesicles [213,214].
A large variety of liposomal formulations was developed by in-
corporating one or more multitasking ligands within the vesicle mem-
brane. Liposomes can exert a passive targeting by enhancing the per-
meability retention time [215] or by depletion of macrophages, as
shown in the case of the hydrophobic drug amphotericin B [216]. On
the other hand, active targeting features can involve the binding me-
chanisms of liposomes towards bioactive receptors, such as antibody
conjugates [217] or permeation enhancers, like cell-penetrating pep-
tides (CPPs) [218]. Stimuli-responsiveness is an attractive perspective
for speciﬁcally triggered drug release towards liposomes, aiming to
reduce the side eﬀects of unspeciﬁc targeting through a dual action.
Within such an approach, the therapeutic cargo can be released in the
cytoplasm by targeting the lower pH inside the endosome, while pro-
viding for conformational changes of dioleylphosphoethanolamine
(DOPE) and cholesterylhemisuccinate [219]. At present, doxorubicin is
one of the most studied drugs for liposomal triggered-release, with a
thermosensitive formulaton, ThermoDox®, in clinical trials. Other li-
posomal formulations with small bioactive molecules are available in
the market, with good encapsulation eﬃciency. Nevertheless targeted
formulations or stimuli-responsive liposomes are still challenging at a
research stage.
The main reason for such a limited transfer of liposomal formulation
into the biopharmaceutical market relies on the drawback of their low
physico-chemical stability, due to the intrinsic poor aqueous solubility
of phospholipids, which tend to aggregate into bigger clusters [220]. As
a consequence, liposome suspensions are usually lyophilized and stored
as dry products [221].
6.3. Non-liposomal nanovesicles
The limited eﬃcacy of liposomes broadens research horizons to-
wards employing lipids in combination with alternative self-assembling
materials, such as surfactants [222,223], polymers [224] and peptides
[225].
Non-liposomal nanovesicles can be classiﬁed according to the al-
ternative component versus phospholipid: niosomes, sphingosomes,
pharmacosomes and quatsomes.
Niosomes are prepared by hydrating a mixture of lipids with non-
ionic surfactants, such as alkyl ethers, alkylesters alkylamides, fatty
acids and amino acids. Niosomes are able to encapsulate both hydro-
philic and hydrophobic drugs. The use of cholesterol as lipid component
leads to more rigid and less leaky bilayers, which makes it particularly
suitable for small drugs such as calcein [226] or poorly soluble beclo-
methasone dipropionate [223]. Niosomes exhibit an overall short-term
stability, which strongly depends on the additional membrane compo-
nents [227].
Sphingosomes are composed by natural or synthetic sphingolipids,
which form nanovesicles in the form of SUVs and LUVs. Compared to
niosomes, they show an enhanced stability, as well as an improved
resistance against hydrolysis, compared to liposomes. A promising ap-
plication of sphingosomes was found in the encapsulation of alchaloids
like vinorelbine [228].
Normal phospholipids are replaced by lipids covalently bonded to
the API to be delivered, leading to create pharmacosomes. Those
structures demonstrated higher encapsulation eﬃciency than liposomes
[229].
Quatsomes are unilamellar nanovesicles composed by quaternary
ammonium surfactants and sterols (e. g. cholesterol and β-sitosterol)
[230]. Several surfactants were utilized so far: cetrimonium bromide
(CTAB), myristalkonium chloride (MKC) and cetylpyridinium chloride
(CPC). Their unilamellar and homogeneous morphology proposes these
nanovesicles as excellent candidates for stable functionalization aimed
to passive targeting [214]. Their key features consist of their very low
Fig. 7. Schematic representation of the main lipid based
nanovesicular systems. According to their size and lamellar
levels, vesicles can be classiﬁed as (left to right): SUV (Small
Unilamellar Vesicles), LUV (Large Unilamellar Vesicles),
GUV (Giant Unilamellar Vesicles), MLV (Multi-Lamellar
Vesicles) and MVV (Multi Vesicular Vesicles).
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size, good dispersion, as well as the remarkable and long-term stability
[231].
Conventional fabrication methods like TFH were combined with
size reducing post formation steps. Extensively studied examples are
ultrasound sonication, proposed for liposomal encapsulation of antic-
ancer drugs [232], extrusion reduced polydispersity and size of nio-
somes loaded with tretinoin [233] or high-pressure homogenization
with a uniform dispersion of SUVs containing the poorly soluble drug
fenoﬁbrate [234]. The most novel technologies are based on com-
pressed ﬂuids (CFs) [214,235], microﬂuidics [211,232] and freeze-
drying of emulsions [236]. In compressed ﬂuid technology (CFs), the
gas is rapidly pressurized, which modulates the solvent density and
solubilization power. Fast density variations are more signiﬁcant by
crossing the critical point towards a phase transition. The broadest ﬂuid
employed in this ﬁeld is carbon dioxide (CO2) thanks to its mild critical
conditions (Pc = 74 bar, Tc = 30.95 °C), which allow the application to
thermosensitive compounds. Within this group, it is worth to mention
the Depressurization of Expanded Liquid Organic Solution-SUSPension
(DELOS SUSP) [214,231] and DESAM (Depressurization of an Ex-
panded Solution into Aqueous Media) [237].
Another unconventional method for nanovesicles production is
based on the freeze-drying of emulsions. Herein, the hydrophilic (i. e.
drug and/or cryoprotectant) and hydrophobic components (i. e. drugs
and lipids) are dissolved in water and organic phase respectively,
leading to an emulsion. The mentioned emulsion is freeze-dried and the
solid pellet is resuspended, prior to its use. Several small molecule
drugs, including hydrophobic (e. g. ﬂurbiprofen), hydrophilic (e. g.
paeoniﬂorin) and amphiphilic (e. g. barberin) APIs, were encorporated
into liposomal SUVs [236].
The new generation of nanovesicles shows complementary features
compared to liposomes, overcoming most of their drawbacks in terms of
formulation stabililty, easy technology and cost-eﬀectiveness. Besides
liposomes have already shown a complete potential as nanocarriers,
non-liposomal L-NVs propose as promising frontiers, from the lab bench
to clinical practice.
7. Nanocarriers for bioimaging and diagnostic
High-resolution cellular and tissue imaging is a highly inter-
disciplinary ﬁeld, merging expertise in materials chemistry, nano-
technology, biology, physics and medicine. In this context, optical and
ﬂuorescent imaging is a research branch of increasing interest because
is non-invasive, involves the use of visible, ultraviolet and infrared light
decreasing the exposure to harmful radiation, and can produce images
of organs, soft tissue and cells both in vitro and in vivo.
Applications of ﬂuorescent carriers span from in vitro biologically
relevant processes associated with diseases and aberrant situation (i.e.
cancers) to in vivo imaging of biological pathways. Thus, the main
characteristics for a colloidal platform involve highly tunable size and
surface, ability to further target the cell surface with enzyme-binding
motifs penetration and imaging capabilities. Over the past years,
ﬂuorescent carriers have been developed for both localization of spe-
cialized nanoparticles in the cells and diagnostic applications. This
elegant approach allowed nanoparticles cellular uptake and their
compartmentalization in speciﬁc tissues, with multi-tasking features.
Indeed, ﬂuorescent delivery systems represent a non-invasive technique
to study live events at a molecular level, as well as diagnostic tool,
which can identify abnormalities on patients, before or after the de-
velopment of the disease.
One of the main strategies to enhance bio-imaging rely on the de-
velopment of imaging probes for the biologically relevant near infrared
(NIR) and far-red region, where tissue exhibit minimal absorbance
[238]. Therefore, the development of new organic dies molecule
emitting in the far-red and NIR region demonstrated increasing interest
over the scientiﬁc community [239]. These molecules are able to re-
duce the tissue auto-ﬂuorescence and allow a high resolution imaging
with deeper tissue penetration.
In this context, Carbon Nano Materials (CNMs) have been proposed
for biomedical application, due to their low toxicity, small size, and
large surface area. Surface functionalization on these materials is pos-
sible and well explored, usually through chemical reaction directly with
the sp2 carbon atoms present on the material surface. This allows their
surface modiﬁcation to make CNMs soluble in aqueous environments
and biocompatible, besides readily internalized by cells. On the other
hand this chemically controlled surface functionalization both by
covalent and noncovalent approach (e.g π-π stacking), allowed chemist
to create specialized nanoparticle speciﬁc for bioimaging. Moreover,
some CNMs such as single walled carbon nanotubes (SWCNTs) [240],
carbon dots (CDs) [241] and graphene, can also act as imaging agents
themselves, due to their intrinsic optical properties [242].
Multi-shell fullerenes, known as carbon nano-onions (CNOs), have
recently gathered great interest among researchers and have been
successfully applied in a variety of diﬀerent ﬁelds of application such as
energy storage [243,244], catalysis [245], supercapacitors [246] and
imaging [247].
CNOs are attractive platforms for imaging, diagnostic and ther-
apeutic applications, thanks to their small size. Moreover, their surface
can be chemically modiﬁed modulating cell penetration and cell re-
cognition respectively [150]. Recent reports showed that ﬂuorescently
labelled CNOs, with an average of 5 nm, exhibit weak inﬂammatory
potential and a low cytotoxicity [248]. They are readily internalized by
cancer cells and deposited in the lysosomes [249,250]. Toxicological
studies were conducted on ﬂuorescein-functionalized CNOs both in vitro
and in vivo. A comparison among the abovementioned functionalized
CNOs and functionalized carbon nanotubes (CNTs) in terms of cyto-
toxicity and immunomodulatory properties demonstrated that CNOs
exhibit eﬃcient cellular uptake and reveal a bright ﬂuorescence signal
[248]. These biologically relevant features proposed CNOs at the
forefront for biomedical applications. Moreover, in vivo studies on
zebraﬁsh (Danio rerio) in the development stage, conﬁrmed their eco-
compatibility and homogenous distribution in a vertebrate model
system, exhibiting excellent performances as biomedical probes [251].
An example of multi-functionalized CNOs (f-CNOs) as targeted delivery
system have been reported, where CNOs were surface functionalized
with ﬂuorescein and folic acid moieties for both imaging and targeting
of cancer cells [250]. The f-CNOs showed a bright ﬂuorescence and a
selective and rapid internalization in cancer cells (HeLa and KB cells)
without toxicity. The f-CNOs were localized into speciﬁc cell com-
partments using a correlative approach with confocal and transmission
electron microscopy [250] (Fig. 8).
Fullerene C60 is a symmetrical sphere made of carbon atoms with a
diameter of 1 nm, which has been widely used for biomedical appli-
cation. Nevertheless the increasing interest on other CNMs such as
CNTs and graphene, several examples of fullerene used for drug de-
livery and bio-imaging are present in literature. For examples, bio-
compatible color-tunable photoluminescent fullerene nanomaterials
were synthetized by conjugating C60 particles with tetraethylene glycol
(TEG) molecules [252]. Their high quantum yield and water solubility
make them suitable for bio-imaging application. Recently a bio-
compatible and water-soluble mesoporous silica nanoparticle (MSN)
coated with fullerene molecules was reported for the drug release of
doxorubicin (DOX) in a mild acidic environment [253]. Furthermore,
C60-modiﬁed MSN showed a green ﬂuorescence of peculiar interest for
cellular imaging.
Several carbon nanomaterials are known to emit ﬂuorescence light
upon photo-excitation [242]. The leading examples on CNMs with in-
trinsic optical properties are semiconducting SWCNTs, which show a
structure dependent ﬂuorescence in the biologically important
1300–1400 nm near-infrared window (NIR-IIa window).
The live imaging of mouse cerebral vasculature using SWCNTs was
previously achieved without craniotomy, cranial windows and skull
thinning techniques, which are usually required [254]. The reduced
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short-wavelength photon scattering in the NIR-IIa window, allowed an
improved imaging resolution to a depth of> 2 mm using three-di-
mensional in vivo imaging through confocal or two-photon techniques.
Carbon nanotubes oﬀer also a promising tool as drug delivery system,
due to their spectroscopic properties and easy surface functionalization.
Targeted drug delivery system have been reported with CNTs where a
drug is loaded on their surface, either covalently or by adsorption, to-
gether with a ligand to facilitate the targeting of selective cancer cells.
An example is the loading of DOX on SWCNTs through π-π stacking
which is feasible due to the aromatic moiety of the drug [255,256]. The
DOX was loaded on a high ratio on the SWCNTs surface, and the drug
was readily released within the acidic tumor microenvironment. Simi-
larly to the adsorption of an aromatic drug molecule, an aromatic or-
ganic dye molecule can be absorbed on the surface of CNMs. For in-
stance boron dipyrromethene (BODIPY)–pyrene/CNTs [257] and
pyrene–BODIPY/CNOs [258] hybrids have been reported as imaging
probes, where pyrene is used as an anchoring group.
Similarly to SWCNTs, CDs are biocompatible carbon-based nano-
particles with intrinsic ﬂuorescence, bypassing possible issues related to
multiple functionalization steps with small organic ﬂuorophore mole-
cules. Moreover, their surface can be chemically modiﬁed allowing
their functionalization with a therapeutic agent and a speciﬁc ligand to
apply them as a targeted drug delivery system. With a diameter below
10 nm and their low toxicity, they are widely used for biomedical ap-
plications. Favourable characteristic of CDs are their size- and excita-
tion wavelength- dependent photoluminescence (PL) behavior, high
stability and resistance to photo bleaching. Biocompatibility studies and
bio distribution of CDs have been explored on zebraﬁsh as a vertebrate
model, proving their compatibility with life and validating their ap-
plication as multi-color imaging probe [259].
CDs have a tunable emission wavelength, depending on the
excitation wavelength, and their reported ﬂuorescence wide-ranged
from NIR [260], to visible [241], to deep ultraviolet [261]. Their ver-
satile optical properties allowed them to be employed in several bio-
medical applications, from in vivo imaging to drug delivery.
Further carbon-based structures, fullerene [262] and CNTs [263],
have been proposed for the development of new MRI contrast agents. In
detail, fullerenes can encapsulate gadolinium, decreasing its toxicity.
An example is represented by gadolinium (Gd)-containing C80 en-
dohedrals (Trimetaspheres™, TMS, Gd3N@C80), which were used as
Atherosclerotic Targeting Contrast Agents (ATCA) for cardiovascular
magnetic resonance (CMR) [264]. Furthermore, gadolinium-functio-
nalized MWCNTs were recently studied as contrast agents for MRI cell
labelling and tracking [263].
Multi-modal molecular imaging approach has been proposed, by a
synergistic combination of two or more detection techniques [265].
Examples of the “dual active” method include the development of na-
noparticles combining ﬂuorescence and magnetic resonance imaging:
they merge eﬀectively the high sensitivity of the ﬂuorescence phe-
nomenon with the high spatial resolution of MRI.
CNMs are quite promising for biomedical applications, as imaging
tools, due to their small size, biocompatibility and optical character-
istics. Besides their intrinsic optical properties and resistance to photo
bleaching, their quantum yield is lower than small organic molecule.
However, a merged strategy with synthetic dyes and CNMs hybrids can
lead to extremely powerful imaging probe for both in vitro and in vivo
applications.
8. Conclusions and future outlooks
Self-assembly mechanisms mimick biological processes by re-
capitulating morphological structure and organization of native tissues.
Fig. 8. High resolution TEM image (A) and AFM topograph
(B) of pristine CNOs. Confocal microscopy of C57BL/6
BMDCs incubated in the presence of ﬂuorescein-CNOs
(green), stained with wheat germ agglutinin-Alexa
Fluor594 (red) and nuclei stain Hoescht (blue) (C). (A), (B)
and (C) are reproduced from [248], Copyright 2013 Wiley-
VCH Verlag GmbH & Co. KGaA. Reproduced with permis-
sion. (D) Representative optical images of zebraﬁsh ex-
posed to BODIPY-CNOs (green). Maximum intensity pro-
jections of the superior part (left) and tail (right) (Scale
bars, 100 μm). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web
version of this article.)
Reprinted with permission from [251]. Copyright 2016
Nature Publishing Group.
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Overall, all strategies discussed herein, explain the use of diﬀerent
colloidal systems to be employed for a tailored bioactive molecule
depot. These strategies depend on the hierarchical and functional
complex stuctures involved, including the target living tissues. The
functional design of the constructs is encoded by the properties of the
fundamental units. The tunable characteristics of the systems generated
therefore, can ensure precise release of bioactive factors or induce a
conformational change at the tissue interface. Thus, controlled fabri-
cation and selection of colloidal-based scaﬀolds can help in rapid de-
velopment of cost-eﬀective engineered solutions for clinical use.
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